WO2001013877A1 - A method for reducing skin irritation and sting from weak carboxylic acid - Google Patents

A method for reducing skin irritation and sting from weak carboxylic acid Download PDF

Info

Publication number
WO2001013877A1
WO2001013877A1 PCT/EP2000/007303 EP0007303W WO0113877A1 WO 2001013877 A1 WO2001013877 A1 WO 2001013877A1 EP 0007303 W EP0007303 W EP 0007303W WO 0113877 A1 WO0113877 A1 WO 0113877A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
sting
skin
water
peg
Prior art date
Application number
PCT/EP2000/007303
Other languages
French (fr)
Inventor
Surajit Mukherjee
Donald Rick
Stephan Samuel Habif
Original Assignee
Unilever Plc
Unilever Nv
Hindustan Lever Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Plc, Unilever Nv, Hindustan Lever Limited filed Critical Unilever Plc
Priority to AU69881/00A priority Critical patent/AU6988100A/en
Publication of WO2001013877A1 publication Critical patent/WO2001013877A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86Polyethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant

Definitions

  • This invention relates to a cosmetic method for reducing skin irritation and sting from weak carboxylic acid by polyethylene glycol .
  • Cosmetic products which improve the appearance of skin are increasingly popular with consumers. Frequently, consumers seek to alleviate or delay the signs of aged or photo-aged skin, such as fine lines and wrinkles, dry and sagging skin.
  • hydroxy acids and several other weak carboxylic acids have been proven to deliver cosmetic benefits, such as improvement in the appearance of photo- -damaged or naturally aged skin, skin lightening, treatment of age spots, etc.
  • their use at high concentrations may occasionally be associated with skin irritation, e.g. skin redness and stinging sensation upon application.
  • these actives are most often delivered as oil-in-water emulsions.
  • the final composition pH should be higher than 3 in order to prevent deleterious effects to skin tissues and unacceptable levels of irritation.
  • Water soluble weak acids when delivered from an oil-in-water emulsion at acidic pH often induce high levels of sting. The sting occurs immediately after application, reaches a maximum intensity usually by 5-8 minutes after application and then begins to reduce in intensity.
  • the irritation can be ameliorated by lowering the amount of an active ingredient in the composition or by reducing the active's penetration through the skin.
  • a serious drawback of both approaches is that the efficacy is impaired.
  • the weak acid related irritation can be reduced by raising the composition's pH but this method yields reduced efficacy due to a decreased acid penetration through the skin. It is desirable to reduce or eliminate the irritation potential of weak acids while maintaining their efficacy.
  • Polyethylene glycol has been used in cosmetic compositions, which also contain an alpha hydroxy acid. See for instance US Patent 5,863,943 (Groh et al . ) and US Patent 5,411,734 (Vargas et al . ) .
  • the prior art described above does not disclose the anti- sting or anti-irritant ability of polyethylene glycol.
  • the invention provides a method for reducing skin irritation caused by the topical application of a composition containing a weak carboxylic acid, the method comprising topically applying polyethylene glycol in a cosmetically acceptable vehicle.
  • the present invention is based, at least on part, on the discovery that polyethylene glycol reduces the sting and/or irritation that may be caused by weak carboxylic acids, without impairing their delivery to the skin.
  • skin as used herein includes the skin on the face, neck, chest, back, arms, armpits, hands and scalp.
  • the molecular weight herein is expressed in Dalton (D) .
  • Polyethylene glycol (PEG) is a water-soluble, thermoplastic polymer produced by the heterogeneous polymerisation of ethylene oxide.
  • the white, free- flowing resins are characterised by the following structural formula: -(-CH 2 CH 2 0-) n .
  • the molecular weight of PEGs suitable for use in the present invention generally ranges from 200 D to several (e.g. five) million D, preferably from 200 D to 20 KD, to maintain anti-irritation efficacy, yet to minimise an increase in formulation viscosity.
  • the amount of polyethylene glycol in the inventive composition ranges from 0.1 to 20%, preferably from 1 to 15%, most preferably from 0.5 to 10%.
  • a weak carboxylic acid suitable for use in the inventive compositions is an acid with a dissociation constant, pKa, of above about 2.
  • pKa a dissociation constant
  • the pKa is above about 3, most preferably in the range of from about 3 to about 5.
  • lactic acid-lactate ion is an example of a conjugate acid-base pair.
  • Acids so defined can only manifest their properties by reacting with bases.
  • acids react with water, the latter acting as a base:
  • pK a is the negative logarithm of K a , and is equal to the pH at which the concentrations of HA and A " are equal.
  • the pK a for alpha hydroxy acids is generally from 2-4, for monocarboxylic acids from 3-5, for alpha amino acids from 2-3; and for salicylic acid it is 3.0.
  • the pK a of a weak water-soluble acid is obtained by titrating it with a strong base such as sodium hydroxide (NaOH) .
  • a strong base such as sodium hydroxide (NaOH)
  • a procedure for determining pKa for a known weak acid is as follows: The following materials are needed: a sample of pure acid for which pKa is to be determined; C0 2 -free deionized distilled water (prepared by boiling deionized distilled water for 5 minutes); Commercial 0. IN NaOH volumetric standard, certified to 0.1005-0.0995 N, eg. Fisher Scientific SS276; 100-ml calibrated glass burette; 125-ml Erlenmeyer flask pH meter, e.g. Corning Model 140 with standard combination electrode for pH; pH buffers, pH 4.00, 7.00, and 10.00, certified to ⁇ 0.01 pH unit at 25, e.g. Fisher Scientific SB101, SB107, and SB115 magnetic stirrer.
  • the pH electrode is inserted into the acid solution and positioned and secured so that it does not interfere with the stirring bar.
  • the initial pH is recorded.
  • gentle stirring is begun such that the pH reading is not affected.
  • the burette is positioned over the flask to allow incremental addition of the 0.1 N standard NaOH to the 0.1 N acid solution.
  • the initial pH is verified and incremental addition of the base begun.
  • the volumes of base added and the resulting pH readings are recorded.
  • the aim is to record pH changes of 0.2 to 0.3 units or volume increases of about 5ml, whichever comes first. Incremental additions are continued until at least 60 ml of the base have been added and the steep change in pH levels off .
  • the data is plotted with the volume of base as the x- axis and pH as the y-axis. The points observed are plotted and a smooth line drawn through them.
  • the volume of base added to obtain the equivalence point is determined, i.e. the volume at which one normal- equivalent of base has been added and the acid has been completely neutralised.
  • the equivalence point volume corresponds to the volume of base at the vertical portion of the curve. If the steep portion of the curve is not vertical, the equivalence point can be obtained by locating the volumes of the base at the two end points that bracket the steep change in pH. The mean of the two volumes is the equivalence point.
  • the midpoint of the titration is the point at which 0.5 normal -equivalents of base have been added, and the acid has been one-half (50%) neutralised.
  • the pH corresponding to the midpoint of the titration is the pK a of the acid. This is the pH at which 50% of the acid has been neutralised, that is, the molecule exists 50% in the non-ionised form and 50% as the anion.
  • suitable weak carboxylic acids include but are not limited to: alpha- or beta-hydroxyacids, dicarboxylic acids, tricarboxylic acids, ascorbic acid, oxamic acid and mixtures thereof.
  • Preferred carboxylic acids, due to their anti-ageing efficacy, are:
  • the amount of weak acid in the inventive composition ranges from 0.01 to 20, preferably from 1 to 15 and most preferably from 2 to 12, by weight of the composition.
  • the acid may be present as a salt, e.g. an ammonium, potassium or sodium salt.
  • compositions employed in the inventive method may have any pH in the general range of 2.5 to 10, the inventive methods are particularly useful in compositions having an acidic pH, preferably 3-6 and most preferably at a pH of 3-5, because such compositions, although efficacious, are particularly irritating.
  • compositions employed in the invention comprise a cosmetically acceptable vehicle to act as a diluant, dispersant or carrier for weak carboxylic acid and PEG, so as to facilitate their distribution when the composition is applied to the skin.
  • the vehicle may be aqueous or an emulsion. Water when present will be in amounts which may range from 5 to 99%, preferably from 40 to 90%, optimally from 50 and 85% by weight .
  • the vehicle is preferably at least 50 wt . % water by weight of the vehicle.
  • the compositions are preferably oil -water emulsions, in order to improve dermal delivery of hydroxy acids (See Sah et al . in J. Cosmet . Sci . 49 , 257 -273 , 1998) . Such improved delivery is frequently accompanied by increased irritation/sting, making the use of PEG in such emulsions particularly critical.
  • water comprises at least 50 wt . % of the inventive emulsion, most preferably from 50 to 85 wt.%, by weight of the composition.
  • relatively volatile solvents may also serve as carriers within compositions employed in the present invention.
  • monohydric C_-C 3 alkanols include ethyl alcohol, methyl alcohol and isopropyl alcohol .
  • the amount of monohydric alkanol may range from 1 to 70%, preferably from 10 to 50%, optimally between 15 and 40% by weight.
  • Emollient materials may also serve as cosmetically acceptable carriers. These may be in the form of silicone oils and synthetic esters. Amounts of the emollients if present may range anywhere from 0.1 to 50%, preferably between 1 and 20% by weight.
  • Silicone oils may be divided into the volatile and non-volatile variety.
  • volatile refers to those materials which have a measurable vapour pressure at ambient temperature.
  • Volatile silicone oils are preferably chosen from cyclic or linear polydimethylsiloxanes containing from 3 to 9, preferably from 4 to 5, silicon atoms. Linear volatile silicone materials generally have viscosities less than about 5 centistokes at 25 °C while cyclic materials typically have viscosities of less than about 10 centistokes.
  • Nonvolatile silicone oils useful as an emollient material include polyalkyl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers .
  • the essentially nonvolatile polyalkyl siloxanes useful herein include, for example, polydimethyl siloxanes with viscosities of from about 5 to about 25 million centistokes at 25°C.
  • the preferred non-volatile emollients useful in the present compositions are the polydimethyl siloxanes having viscosities from about 10 to about 400 centistokes at 25°C.
  • Suitable emollients are:
  • Alkenyl or alkyl esters of fatty acids having fromlO to 20 carbon atoms examples thereof include isoarachidyl neopentanoate, isononyl isonanonoate, oleyl myristate, oleyl stearate, and oleyl oleate.
  • Ether-esters such as fatty acid esters of ethoxylated fatty alcohols.
  • Ethylene glycol mono and di-fatty acid esters diethylene glycol mono- and di-fatty acid esters, polyethylene glycol (200-6000) mono- and di-fatty acid esters, propylene glycol mono- and di-fatty acid esters, polypropylene glycol 2000 monooleate, polypropylene glycol 2000 monostearate, ethoxylated propylene glycol monostearate, glyceryl mono- and di-fatty acid esters, polyglycerol poly-fatty esters, ethoxylated glyceryl monostearate, 1,3 -butylene glycol monostearate, 1,3 -butylene glycol distearate, polyoxyethylene polyol fatty acid ester, sorbitan fatty acid esters, and polyoxyethylene sorbitan fatty acid esters are satisfactory polyhydric alcohol esters.
  • Wax esters such as beeswax, spermaceti, myristyl myristate, stearyl stearate and arachidyl behenate.
  • Sterols esters of which cholesterol fatty acid esters are examples thereof.
  • Fatty acids having from 10 to 30 carbon atoms may also be included as cosmetically acceptable carriers for compositions of this invention.
  • Illustrative of this category are pelargonic, lauric, myristic, palmitic, stearic, isostearic, hydroxystearic, oleic, linoleic, ricinoleic, arachidic, behenic and erucic acids.
  • Thickeners may also be utilised as part of the cosmetically acceptable carrier of compositions according to the present invention.
  • Typical thickeners include crosslinked acrylates (e.g. Carbopol 982), hydrophobically-modified acrylates (e.g. Carbopol 1382), cellulosic derivatives and natural gums.
  • useful cellulosic derivatives are sodium carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose and hydroxymethyl cellulose.
  • Natural gums suitable for the present invention include guar, xanthan, sclerotium, carrageenan, pectin and combinations of these gums.
  • Amounts of the thickener may range from 0.0001 to 5%, usually from 0.001 to 1%, optimally from 0.01 to 0.5% by weight.
  • the water, solvents, silicones, esters, fatty acids, and/or thickeners will constitute the cosmetically acceptable carrier in amounts from 1 to 99.9%, preferably from 80 to 99% by weight.
  • an oil or oily material may be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophilic-lipophilic balance (HLB) of the emulsifier employed.
  • HLB hydrophilic-lipophilic balance
  • Surfactants may also be present in cosmetic compositions of the present invention. Total concentration of the surfactant will range from 0.1 to 40%, preferably from 1 to 20%, optimally from 1 to 5% by weight of the composition.
  • the surfactant may be selected from the group consisting of anionic, nonionic, cationic and amphoteric surfactants.
  • nonionic surfactants are those with a C 10 -C 20 fatty alcohol or acid hydrophobe condensed with from 2 to 100 moles of ethylene oxide or propylene oxide per mole of hydrophobe; C 2 -C 10 alkyl phenols condensed with from 2 to 20 moles of alkylene oxide; mono- and di- fatty acid esters of ethylene glycol; fatty acid monoglyceride; sorbitan, mono- and di- C 8 -C 20 fatty acids; block copolymers (ethylene oxide/propylene oxide) ; and polyoxyethylene sorbitan as well as combinations thereof.
  • Alkyl polyglycosides and saccharide fatty amides are also suitable nonionic surfactants.
  • Preferred anionic surfactants include soap, alkyl ether sulfate and sulfonates, alkyl sulfates and sulfonates, alkylbenzene sulfonates, alkyl and dialkyl sulfosuccinates, C 8 -C 20 acyl isethionates , acyl glutamates, C 8 -C 20 alkyl ether phosphates and combinations thereof .
  • Actives are defined as skin benefit agents other than emollients and other than ingredients that merely improve the physical characteristics of the composition. Although not limited to this category, general examples include additional anti-sebum ingredients and sunscreens.
  • Sunscreens include those materials commonly employed to block ultraviolet light.
  • Illustrative compounds are the derivatives of PABA, cinnamate and salicylate.
  • avobenzophenone Parsol 1789 ®
  • octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone also known as oxybenzone
  • Octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3 , respectively.
  • the exact amount of sunscreen employed in the compositions can vary depending upon the degree of protection desired from the sun's UV radiation.
  • Suitable preservatives include alkyl esters of p-hydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds. Particularly preferred preservatives of this invention are methyl paraben, propyl paraben, phenoxyethanol and benzyl alcohol. Preservatives will usually be employed in amounts ranging from about 0.1% to 2% by weight of the composition.
  • composition employed in the invention is intended primarily as a product for topical application to human skin, especially as an agent to improve the appearance of aged or photoaged skin.
  • a quantity of the composition for example from 1 to 100 ml, is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device.
  • a quantity of the composition for example from 1 to 100 ml, is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device.
  • This example measured sting caused by formulations containing glycolic acid.
  • Procedure for in-vivo sting test This was a randomized, double blind study where each subject evaluated one test formulation and a control formulation or two test formulations on contralateral nasolabial folds. During the qualification phase, each subject evaluated an 8% glycolic acid test versus a vehicle control (0% glycolic) . Subjects with established left/right balanced sensitivity to glycolic acid were qualified. A maximum of 20 qualified subjects (minimum of 15) were utilized in each subsequent test. One paired comparison was made on each testing day, with a minimum of 3 days between sting testing throughout the study. Subjects underwent a 15 second Ivory soap wash regime immediately prior to product testing for enhancing sting response. Any subjects experiencing any stinging/burning on the test sites immediately prior to product application did not have products applied.
  • Study personnel then applied one test formulation and one control or test formulation simultaneously to the appropriate left/right test site, and gently but thoroughly rubbed in. Subjects compared the stinging potential of the two formulations, over a 7.5 minute period using a self-assessment questionnaire.
  • Sting/Burn Propensity The degree of stinging/burning felt on the left and right inner cheek and crease of the nose was evaluated using the following scale at the times indicated in the Tables below:
  • 0 -no stinging / burning 1 -very slight stinging / burning; 2 -slight stinging / burning; 3 - moderate stinging / burning; 4 -moderately high stinging / burning; 5 -high stinging / burning; 6 -extreme stinging / burning.
  • This example measured the effect of PEG 200D on glycolic acid sting at pH 3.8 in Base Formula A.
  • the in-vivo sting test and Base Formula A are described in Example 1.
  • Base Formula A was prepared without the glycolic acid, base, and PEG.
  • the PEG was solubilised in a separate beaker containing glycolic acid + base (ammonium hydroxide) and a small level of water from the formulation (no more than 5% is needed)- thus, the original Base Formula A was originally made with 5% less water.
  • the glycolic acid/PEG solution was then post added to the Base Formula A during the cool down stage (usually at a temperature of about 45°C) .
  • the results obtained are summarised in Tables 2A and 2B.
  • the emulsion concentrate was made using all ingredients except glycolic / base / PEG and without all the water. In a separate beaker glycolic + base + PEG + about 5% of the total water was combined and mixed until the PEG solubilises completely. This mixture was then post added to the emulsion. The pH was then adjusted to the correct pH using base, and then the remainder of the water was added to qs . 100%.
  • Example 1 tested the various compounds for their ability to reduce sting.
  • the test procedure and Base Formula A are described in Example 1.
  • the results obtained are summarised in Tables 6A and 6B .
  • This example tested the effect of polyethylene glycol on the delivery of glycolic acid molecules to the skin layers.
  • transepidermal water loss was determined using a ServoMed EP1 evaporimeter . Skin discs allowing water losses of >5 g/m2 per hr were replaced. The skin discs were dosed with 2 ⁇ L of product containing the nonlabelled active plus an insignificant weight of the active radiolabelled with 3H or 14C at about 30 microCurie/gram product. The dose was delivered via a displaced volume pipette and spread on the 9-mm diameter exposed skin surface with either a latex finger cot stretched over a cotton tip applicator. Contact times were 6 hours, with receptor fluid being sampled at either 1- or 2-hour intervals in scintillation vials.
  • the skin surface was rinsed with three ⁇ l- ml aliquots of water, the skin discs were removed from the apparatus, and blotted with 1/3 of tissue paper (Kim Wipe) .
  • the upper surface was tape-stripped 9 times with Scotch transparent tape to obtain the stratum corneum, and the epidermis was separated from the dermis with a scalpel.
  • Examples 1 - 5 demonstrate that polyethylene glycol reduced the sting caused by weak acids.
  • Other known anti-irritants such as hydrocortisone, as well as a polysaccharide, arabinogalactan, did not reduce the sting caused by weak carboxylic acids (Comparative Example 6) .
  • the addition of PEG did not adversely affect the delivery of actives to skin layers (Example 7) .
  • Example 8 illustrates topical compositions according to the present invention.
  • the compositions can be processed in a conventional manner and are suitable for cosmetic use.
  • the compositions are suitable for application to aged and/or UV-damaged skin to improve the appearance and the feel thereof as well as for application to healthy skin to prevent or retard deterioration thereof.
  • a typical oil-in-water emulsion within the scope of the invention is as follows:
  • a typical water- in-oil dispersion within the scope of the invention is as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

A method for reducing skin irritation and/or sting that may be caused by a weak carboxylic acid by adding polyethylene glycol (PEG). Addition of PEG lowers irritation and sting without reducing the delivery of weak acids to skin tissues.

Description

A METHOD FOR REDUCING SKIN IRRITATION AND STING FROM WEAK
CARBOXYLIC ACID
This invention relates to a cosmetic method for reducing skin irritation and sting from weak carboxylic acid by polyethylene glycol .
Cosmetic products which improve the appearance of skin are increasingly popular with consumers. Frequently, consumers seek to alleviate or delay the signs of aged or photo-aged skin, such as fine lines and wrinkles, dry and sagging skin.
Some ingredients used in topical products are potentially irritating, especially to people with "sensitive skin." Such irritation is commonly perceived as sting or burning.
As an example, hydroxy acids and several other weak carboxylic acids have been proven to deliver cosmetic benefits, such as improvement in the appearance of photo- -damaged or naturally aged skin, skin lightening, treatment of age spots, etc. Unfortunately, their use at high concentrations may occasionally be associated with skin irritation, e.g. skin redness and stinging sensation upon application. For aesthetic reasons, these actives are most often delivered as oil-in-water emulsions. Practically, the final composition pH should be higher than 3 in order to prevent deleterious effects to skin tissues and unacceptable levels of irritation. Water soluble weak acids when delivered from an oil-in-water emulsion at acidic pH often induce high levels of sting. The sting occurs immediately after application, reaches a maximum intensity usually by 5-8 minutes after application and then begins to reduce in intensity.
The irritation can be ameliorated by lowering the amount of an active ingredient in the composition or by reducing the active's penetration through the skin. A serious drawback of both approaches is that the efficacy is impaired. The weak acid related irritation can be reduced by raising the composition's pH but this method yields reduced efficacy due to a decreased acid penetration through the skin. It is desirable to reduce or eliminate the irritation potential of weak acids while maintaining their efficacy.
One approach to lower the sting is to formulate the acid with a strong alkali metal base. Yu et al . (U.S. patent 4,105,783) suggested the use of ammonium hydroxide or an organic base. Unfortunately, this method raises the pH of the composition and reduces the ability of the weak acid to penetrate the skin, thus lowering its efficacy (see Sah et al . in J. Cos et . Sci . 49 , 257 -273 , 1998) . A clear need exists for a cosmetic composition with a weak acid that reduces sting but does not reduce dermal delivery.
Polyethylene glycol has been used in cosmetic compositions, which also contain an alpha hydroxy acid. See for instance US Patent 5,863,943 (Groh et al . ) and US Patent 5,411,734 (Vargas et al . ) . The prior art described above, however, does not disclose the anti- sting or anti-irritant ability of polyethylene glycol.
The invention provides a method for reducing skin irritation caused by the topical application of a composition containing a weak carboxylic acid, the method comprising topically applying polyethylene glycol in a cosmetically acceptable vehicle. The present invention is based, at least on part, on the discovery that polyethylene glycol reduces the sting and/or irritation that may be caused by weak carboxylic acids, without impairing their delivery to the skin.
Except in the operating and comparative examples, or where otherwise explicitly indicated, all numbers in this description indicating amounts of material or conditions of reaction, physical properties of materials and/or use are to be understood as modified by the word "about." All amounts are by weight of the composition, unless otherwise specified. The term "skin" as used herein includes the skin on the face, neck, chest, back, arms, armpits, hands and scalp.
The terms "irritation", "sting", and "burn", "inflammation", and "redness" as used herein are synonymous and are used interchangeably.
The molecular weight herein is expressed in Dalton (D) . The numerical terms followed by the letters "KD" denoting molecular weight of a compound, to be read as the numerical term x 1,000 e.g. 10KD means molecular weight of 10,000 D)
Polyethylene glycol (PEG) is a water-soluble, thermoplastic polymer produced by the heterogeneous polymerisation of ethylene oxide. The white, free- flowing resins are characterised by the following structural formula: -(-CH2 CH20-)n. The molecular weight of PEGs suitable for use in the present invention generally ranges from 200 D to several (e.g. five) million D, preferably from 200 D to 20 KD, to maintain anti-irritation efficacy, yet to minimise an increase in formulation viscosity. The amount of polyethylene glycol in the inventive composition ranges from 0.1 to 20%, preferably from 1 to 15%, most preferably from 0.5 to 10%.
A weak carboxylic acid suitable for use in the inventive compositions is an acid with a dissociation constant, pKa, of above about 2. Preferably, the pKa is above about 3, most preferably in the range of from about 3 to about 5.
An acid is a species having a tendency to lose a proton, while a base is a species having a tendency to accept a proton. Hence for every acid, HA, there is a conjugate base A" :
HA = H+ +A~
Thus, lactic acid-lactate ion is an example of a conjugate acid-base pair.
Acids so defined can only manifest their properties by reacting with bases. In aqueous solutions, acids react with water, the latter acting as a base:
HA +H20 <=> H30+ + A"
Quantitatively, the acid strength of HA, relative to the base strength of water is given by the equilibrium constant expression by the equation:
K= [H30+] [A'] / [H20] [HA]
where parentheses denote molar concentrations. As almost all measurements are made in dilute aqueous solution, the concentration of water remains essentially constant and its activity can be taken as unity. Letting H+ represent the solvated proton, we have:
Ka = [H+] [A"]/ [HA] ,
where Ka is the acidic dissociation (or ionization) constant. This equation can be written in the form:
pKa =pH +log [HA] / [A"]
where pKa is the negative logarithm of Ka , and is equal to the pH at which the concentrations of HA and A" are equal.
The pKa for alpha hydroxy acids is generally from 2-4, for monocarboxylic acids from 3-5, for alpha amino acids from 2-3; and for salicylic acid it is 3.0.
The pKa of a weak water-soluble acid is obtained by titrating it with a strong base such as sodium hydroxide (NaOH) . The intercept at the midpoint of the titration, i.e. the point at which 0.5 molar equivalents of base have been added, is numerically equal to the pKa of the acid.
A procedure for determining pKa for a known weak acid is as follows: The following materials are needed: a sample of pure acid for which pKa is to be determined; C02 -free deionized distilled water (prepared by boiling deionized distilled water for 5 minutes); Commercial 0. IN NaOH volumetric standard, certified to 0.1005-0.0995 N, eg. Fisher Scientific SS276; 100-ml calibrated glass burette; 125-ml Erlenmeyer flask pH meter, e.g. Corning Model 140 with standard combination electrode for pH; pH buffers, pH 4.00, 7.00, and 10.00, certified to ±0.01 pH unit at 25, e.g. Fisher Scientific SB101, SB107, and SB115 magnetic stirrer.
All glassware and equipment must be clean and acid- washed if necessary. At least 50 ml of a 0.1 Normal solution of the acid for which the pKa is to be determined is prepared in C02-free distilled water. Avoid introducing C02 to the solution by avoiding excessive shaking. The final solution is capped until use. The pH meter is calibrated using three buffers at pH 7.00, 3.00, and 10.00, according to the pH meter manufacturer's instructions. The electrode is rinsed with distilled water between samples. The burette is filled with a 0.1 N NaOH standard solution. 50.0 ml of 0.1 N acid solution is added to a 125-ml Erlenmeyer and a stirring bar added. The pH electrode is inserted into the acid solution and positioned and secured so that it does not interfere with the stirring bar. The initial pH is recorded. Gentle stirring is begun such that the pH reading is not affected. The burette is positioned over the flask to allow incremental addition of the 0.1 N standard NaOH to the 0.1 N acid solution. The initial pH is verified and incremental addition of the base begun. The volumes of base added and the resulting pH readings are recorded. The aim is to record pH changes of 0.2 to 0.3 units or volume increases of about 5ml, whichever comes first. Incremental additions are continued until at least 60 ml of the base have been added and the steep change in pH levels off .
The data is plotted with the volume of base as the x- axis and pH as the y-axis. The points observed are plotted and a smooth line drawn through them. The volume of base added to obtain the equivalence point is determined, i.e. the volume at which one normal- equivalent of base has been added and the acid has been completely neutralised. When the steep portion of the curve is vertical, the equivalence point volume corresponds to the volume of base at the vertical portion of the curve. If the steep portion of the curve is not vertical, the equivalence point can be obtained by locating the volumes of the base at the two end points that bracket the steep change in pH. The mean of the two volumes is the equivalence point. To determine the pKa, first locate the midpoint of the titration by halving (i.e. ÷2 ) the volume of base at equivalence point. The midpoint of the titration is the point at which 0.5 normal -equivalents of base have been added, and the acid has been one-half (50%) neutralised. The pH corresponding to the midpoint of the titration is the pKa of the acid. This is the pH at which 50% of the acid has been neutralised, that is, the molecule exists 50% in the non-ionised form and 50% as the anion.
Examples of suitable weak carboxylic acids include but are not limited to: alpha- or beta-hydroxyacids, dicarboxylic acids, tricarboxylic acids, ascorbic acid, oxamic acid and mixtures thereof. Preferred carboxylic acids, due to their anti-ageing efficacy, are:
ACID pKa glycolic 3.8 lactic 3.8 malic 3.4 beta-hydroxybiutyric 4.7 acetic 4.75 succinic 4.2 citric 3.1 ascorbic 4.1 salicylic 3.0 oxamic 2.4 and mixtures thereof .
The amount of weak acid in the inventive composition ranges from 0.01 to 20, preferably from 1 to 15 and most preferably from 2 to 12, by weight of the composition.
At concentrations below 2% of the acid, there is minimal stinging and the anti-ageing efficacy does not increase significantly above 12%.
It is to be understood that depending on the pH of the composition, the acid may be present as a salt, e.g. an ammonium, potassium or sodium salt.
Although the compositions employed in the inventive method may have any pH in the general range of 2.5 to 10, the inventive methods are particularly useful in compositions having an acidic pH, preferably 3-6 and most preferably at a pH of 3-5, because such compositions, although efficacious, are particularly irritating.
The compositions employed in the invention comprise a cosmetically acceptable vehicle to act as a diluant, dispersant or carrier for weak carboxylic acid and PEG, so as to facilitate their distribution when the composition is applied to the skin.
The vehicle may be aqueous or an emulsion. Water when present will be in amounts which may range from 5 to 99%, preferably from 40 to 90%, optimally from 50 and 85% by weight .
According to the present invention, the vehicle is preferably at least 50 wt . % water by weight of the vehicle. The compositions are preferably oil -water emulsions, in order to improve dermal delivery of hydroxy acids (See Sah et al . in J. Cosmet . Sci . 49 , 257 -273 , 1998) . Such improved delivery is frequently accompanied by increased irritation/sting, making the use of PEG in such emulsions particularly critical. In the preferred oil-in-water emulsions according to the present invention, water comprises at least 50 wt . % of the inventive emulsion, most preferably from 50 to 85 wt.%, by weight of the composition.
Besides water, relatively volatile solvents may also serve as carriers within compositions employed in the present invention. Most preferred are monohydric C_-C3 alkanols. These include ethyl alcohol, methyl alcohol and isopropyl alcohol . The amount of monohydric alkanol may range from 1 to 70%, preferably from 10 to 50%, optimally between 15 and 40% by weight.
Emollient materials may also serve as cosmetically acceptable carriers. These may be in the form of silicone oils and synthetic esters. Amounts of the emollients if present may range anywhere from 0.1 to 50%, preferably between 1 and 20% by weight.
Silicone oils may be divided into the volatile and non-volatile variety. The term "volatile" as used herein refers to those materials which have a measurable vapour pressure at ambient temperature. Volatile silicone oils are preferably chosen from cyclic or linear polydimethylsiloxanes containing from 3 to 9, preferably from 4 to 5, silicon atoms. Linear volatile silicone materials generally have viscosities less than about 5 centistokes at 25 °C while cyclic materials typically have viscosities of less than about 10 centistokes.
Nonvolatile silicone oils useful as an emollient material include polyalkyl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers . The essentially nonvolatile polyalkyl siloxanes useful herein include, for example, polydimethyl siloxanes with viscosities of from about 5 to about 25 million centistokes at 25°C. Among the preferred non-volatile emollients useful in the present compositions are the polydimethyl siloxanes having viscosities from about 10 to about 400 centistokes at 25°C.
Among the suitable emollients are:
(1) Alkenyl or alkyl esters of fatty acids having fromlO to 20 carbon atoms. Examples thereof include isoarachidyl neopentanoate, isononyl isonanonoate, oleyl myristate, oleyl stearate, and oleyl oleate.
(2) Ether-esters such as fatty acid esters of ethoxylated fatty alcohols.
(3) Polyhydric alcohol esters. Ethylene glycol mono and di-fatty acid esters, diethylene glycol mono- and di-fatty acid esters, polyethylene glycol (200-6000) mono- and di-fatty acid esters, propylene glycol mono- and di-fatty acid esters, polypropylene glycol 2000 monooleate, polypropylene glycol 2000 monostearate, ethoxylated propylene glycol monostearate, glyceryl mono- and di-fatty acid esters, polyglycerol poly-fatty esters, ethoxylated glyceryl monostearate, 1,3 -butylene glycol monostearate, 1,3 -butylene glycol distearate, polyoxyethylene polyol fatty acid ester, sorbitan fatty acid esters, and polyoxyethylene sorbitan fatty acid esters are satisfactory polyhydric alcohol esters.
(4) Wax esters such as beeswax, spermaceti, myristyl myristate, stearyl stearate and arachidyl behenate.
(5) Sterols esters, of which cholesterol fatty acid esters are examples thereof.
Fatty acids having from 10 to 30 carbon atoms may also be included as cosmetically acceptable carriers for compositions of this invention. Illustrative of this category are pelargonic, lauric, myristic, palmitic, stearic, isostearic, hydroxystearic, oleic, linoleic, ricinoleic, arachidic, behenic and erucic acids.
Thickeners may also be utilised as part of the cosmetically acceptable carrier of compositions according to the present invention. Typical thickeners include crosslinked acrylates (e.g. Carbopol 982), hydrophobically-modified acrylates (e.g. Carbopol 1382), cellulosic derivatives and natural gums. Among useful cellulosic derivatives are sodium carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose and hydroxymethyl cellulose. Natural gums suitable for the present invention include guar, xanthan, sclerotium, carrageenan, pectin and combinations of these gums. Amounts of the thickener may range from 0.0001 to 5%, usually from 0.001 to 1%, optimally from 0.01 to 0.5% by weight.
Collectively, the water, solvents, silicones, esters, fatty acids, and/or thickeners will constitute the cosmetically acceptable carrier in amounts from 1 to 99.9%, preferably from 80 to 99% by weight.
/An oil or oily material may be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophilic-lipophilic balance (HLB) of the emulsifier employed.
Surfactants may also be present in cosmetic compositions of the present invention. Total concentration of the surfactant will range from 0.1 to 40%, preferably from 1 to 20%, optimally from 1 to 5% by weight of the composition. The surfactant may be selected from the group consisting of anionic, nonionic, cationic and amphoteric surfactants. Particularly preferred nonionic surfactants are those with a C10-C20 fatty alcohol or acid hydrophobe condensed with from 2 to 100 moles of ethylene oxide or propylene oxide per mole of hydrophobe; C2-C10 alkyl phenols condensed with from 2 to 20 moles of alkylene oxide; mono- and di- fatty acid esters of ethylene glycol; fatty acid monoglyceride; sorbitan, mono- and di- C8-C20 fatty acids; block copolymers (ethylene oxide/propylene oxide) ; and polyoxyethylene sorbitan as well as combinations thereof. Alkyl polyglycosides and saccharide fatty amides (e.g. methyl gluconamides) are also suitable nonionic surfactants.
Preferred anionic surfactants include soap, alkyl ether sulfate and sulfonates, alkyl sulfates and sulfonates, alkylbenzene sulfonates, alkyl and dialkyl sulfosuccinates, C8-C20 acyl isethionates , acyl glutamates, C8-C20 alkyl ether phosphates and combinations thereof .
Various types of additional active ingredients may be present in cosmetic compositions of the present invention. Actives are defined as skin benefit agents other than emollients and other than ingredients that merely improve the physical characteristics of the composition. Although not limited to this category, general examples include additional anti-sebum ingredients and sunscreens.
Sunscreens include those materials commonly employed to block ultraviolet light. Illustrative compounds are the derivatives of PABA, cinnamate and salicylate. For example, avobenzophenone (Parsol 1789®) octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone (also known as oxybenzone) can be used. Octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3 , respectively. The exact amount of sunscreen employed in the compositions can vary depending upon the degree of protection desired from the sun's UV radiation.
Many cosmetic compositions, especially those containing water, must be protected against the growth of potentially harmful microorganisms. Preservatives are, therefore, necessary. Suitable preservatives include alkyl esters of p-hydroxybenzoic acid, hydantoin derivatives, propionate salts, and a variety of quaternary ammonium compounds. Particularly preferred preservatives of this invention are methyl paraben, propyl paraben, phenoxyethanol and benzyl alcohol. Preservatives will usually be employed in amounts ranging from about 0.1% to 2% by weight of the composition.
The composition employed in the invention is intended primarily as a product for topical application to human skin, especially as an agent to improve the appearance of aged or photoaged skin.
In use, a quantity of the composition, for example from 1 to 100 ml, is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device. The following specific examples further illustrate the invention, but the invention is not limited thereto.
List of suppliers
Active Ingredient Supplier
Polyethylene Glycol Sigma, Union
Carbide Corp. Arabinogalactan Larex, Inc.
Glycolic acid DuPont
Lactic acid Purac America,
Inc . Hydrocortisone (water soluble) Sigma
EXAMPLE 1
This example measured sting caused by formulations containing glycolic acid.
Procedure for in-vivo sting test: This was a randomized, double blind study where each subject evaluated one test formulation and a control formulation or two test formulations on contralateral nasolabial folds. During the qualification phase, each subject evaluated an 8% glycolic acid test versus a vehicle control (0% glycolic) . Subjects with established left/right balanced sensitivity to glycolic acid were qualified. A maximum of 20 qualified subjects (minimum of 15) were utilized in each subsequent test. One paired comparison was made on each testing day, with a minimum of 3 days between sting testing throughout the study. Subjects underwent a 15 second Ivory soap wash regime immediately prior to product testing for enhancing sting response. Any subjects experiencing any stinging/burning on the test sites immediately prior to product application did not have products applied. Study personnel then applied one test formulation and one control or test formulation simultaneously to the appropriate left/right test site, and gently but thoroughly rubbed in. Subjects compared the stinging potential of the two formulations, over a 7.5 minute period using a self-assessment questionnaire.
Sting/Burn Propensity: The degree of stinging/burning felt on the left and right inner cheek and crease of the nose was evaluated using the following scale at the times indicated in the Tables below:
0 -no stinging / burning; 1 -very slight stinging / burning; 2 -slight stinging / burning; 3 - moderate stinging / burning; 4 -moderately high stinging / burning; 5 -high stinging / burning; 6 -extreme stinging / burning.
Determination of Statistical Significance: At each evaluation time point after baseline, the parametric paired t-test (two-tailed) was performed, to compare the extent of attribute change from baseline between each treatment comprising a paired comparison test, with subject acting as a block in these analyses. (Ref. Sta tis ti cal Methods , Snedecor and Cochran, Iowa State University Press, 7th Edition, 1980, pp. 84-86]). The test can be implemented using the SAS software procedure MEANS with the T and PRT options specified.
Forced choice for stinging/burning: At each evaluation point (0,2.5,5.0 and 7.5 min) , the response to the forced choice assessment "Which side of the face has more stinging?" was analysed as follows: the number of subjects choosing treatment A was compared to the number of subjects choosing treatment B using a parametric paired t-test (2-tailed) . Statistical significance was determined at p < 0.1. Results from several paired comparisons using this assessment method are shown (see later) in Tables IB, 2B, 3B, 4B, and 5B .
An oil-in-water emulsion cream (Base Formula A) was prepared:
Figure imgf000022_0001
*Unless otherwise noted, active levels were approximately 100%.
The sting/burn of Base Formula A with or without 8% glycolic acid was tested using the in-vivo sting test. The results obtained are summarised in Tables 1A and IB
Table 1A
Sting/Burn Propensity
Figure imgf000023_0001
p < 0.05
Table IB
Forced Choice for Stinging/Burning: Which side is worse? Results 7.5 minutes after application
Figure imgf000023_0002
p < 0.05 The sting/burn propensity of glycolic at 8% and 4% level were compared. The results obtained are summarised in Table lC.
Table 1C
Sting/Burn Propensity
Figure imgf000024_0001
* p < 0.05
It can be seen from the results in Tables 1A-1C that 8% glycolic acid at pH 3.8 is significantly more stinging than either the base formulation or 4% glycolic acid. Although stinging can be reduced by increasing pH or lowering the active level, such changes in composition significantly affect dermal delivery and, consequently, the efficacy of the active.
EXAMPLE 2
This example measured the effect of PEG 200D on glycolic acid sting at pH 3.8 in Base Formula A. The in-vivo sting test and Base Formula A are described in Example 1.
Base Formula A was prepared without the glycolic acid, base, and PEG. The PEG was solubilised in a separate beaker containing glycolic acid + base (ammonium hydroxide) and a small level of water from the formulation (no more than 5% is needed)- thus, the original Base Formula A was originally made with 5% less water. The glycolic acid/PEG solution was then post added to the Base Formula A during the cool down stage (usually at a temperature of about 45°C) . The results obtained are summarised in Tables 2A and 2B.
Table 2A.
Sting/Burn propensity
Figure imgf000025_0001
0.1 Table 2B
Forced Choice for Stinging/Burning; Which side is worse?
Results 7.5 minutes after application
Figure imgf000026_0001
It can be seen from the results in Tables 2A and 2B that PEG 200D significantly reduced the stinging/burning propensity of Base Formula A containing 8% glycolic acid.
EXAMPLE 3
This example measured the effect of PEG 8000D on glycolic acid sting at pH 3.8 in Base Formula A. The in-vivo sting test and Base Formula A are described in Example 1. The results obtained are summarised in Tables 3A, 3B, and 3C.
Table 3A
Sting/Burn propensity
Figure imgf000027_0001
0.1
Table 3B
Forced Choice for Stinging/Burning; Which side is worse?
Results: 0 minutes (immediately) after application
Figure imgf000027_0002
p<0.1
Table 3C
Sting/Burn propensity
Figure imgf000028_0001
*p<0.1
It can be seen from the results in Tables 3A and 3B that PEG 8KD significantly reduced the stinging/burning propensity of Base Formula A containing 8% glycolic acid. In Table 3C, the stinging response of Base +8% glycolic + 5% PEG 8KD was less than that of Base + 4% glycolic, significant at 7.5 minutes after application. Thus, it is concluded that addition of 5% PEG 8KD reduced the sting of the formulation containing 8% glycolic acid to less than that of a formulation containing only 4% glycolic acid.
EXAMPLE 4
This example tested the effect of PEG 11KD on glycolic acid sting in a lotion. The test is described in Example 1. The oil-in-water lotion (Base Formula B) was prepared having the following formula:
Figure imgf000029_0001
Figure imgf000030_0001
*Unless otherwise noted, active levels are approximately 100%.
The emulsion concentrate was made using all ingredients except glycolic / base / PEG and without all the water. In a separate beaker glycolic + base + PEG + about 5% of the total water was combined and mixed until the PEG solubilises completely. This mixture was then post added to the emulsion. The pH was then adjusted to the correct pH using base, and then the remainder of the water was added to qs . 100%.
The results obtained are summarised in Tables 4A and 4B
Table 4A
Sting/Burn propensity
Figure imgf000031_0001
* p<0.1
Table 4B
Forced Choice for Stinging/Burning; Which side is worse? Results 2.5 minutes after application
Figure imgf000031_0002
p<0.1 It can be seen from the results in Tables 4A and 4B that PEG IIKD reduced the stinging/burning propensity of Base Formula B containing 8% glycolic acid.
EXAMPLE 5
PEG 8KD was tested for its ability to reduce sting in an additional cream base containing 4% glycolic acid at pH 4.2. The test procedure is described in Example 1. Base Formula C was as follows:
Figure imgf000033_0001
Figure imgf000034_0001
The results obtained are summarised in Tables 5A and 5B
Table 5A
Sting/Burn propensity
Figure imgf000034_0002
rp<0.1
Table 5B
Forced Choice for Stinging/Burning; Which side is worse? Results 2.5 minutes after application
Figure imgf000034_0003
P<0.1 COMPARATIVE EXAMPLE 6
This example tested the various compounds for their ability to reduce sting. The test procedure and Base Formula A are described in Example 1. The results obtained are summarised in Tables 6A and 6B .
Table 6A Hydrocortisone
Figure imgf000035_0001
Table 6B Arabinogalactan
Figure imgf000036_0001
The results in Tables 6A and 6B demonstrate that neither hydrocortisone nor arabinogalactan reduced the sting. In fact, addition of 5% arabinogalactan (Table 6B) slightly enhanced the sting of the anti-ageing cream.
EXAMPLE 7
This example tested the effect of polyethylene glycol on the delivery of glycolic acid molecules to the skin layers.
Procedure: Dermal delivery of actives was measured by the in-vitro percutaneous absorption (PCA) test. The tests were carried out using dermatomed pig skin and Bronaugh flow-through cells' 3-4 week old female dorsal pig skin, rinsed with water only was obtained from Buckshire Farms. The skins were stored at -70°C until use. They were thawed at room temperature, shaved gently with a Norelco electric shaver, sliced to 510 urn thickness using a Padgett Dermatome, punched into 18-mm discs with a cork borer, and mounted in Bronaugh diffusion cells over 37°C, pH 7.1 Hank's balanced salts buffer flowing at 5 ml/min. After 30 min equilibration, transepidermal water loss was determined using a ServoMed EP1 evaporimeter . Skin discs allowing water losses of >5 g/m2 per hr were replaced. The skin discs were dosed with 2 μL of product containing the nonlabelled active plus an insignificant weight of the active radiolabelled with 3H or 14C at about 30 microCurie/gram product. The dose was delivered via a displaced volume pipette and spread on the 9-mm diameter exposed skin surface with either a latex finger cot stretched over a cotton tip applicator. Contact times were 6 hours, with receptor fluid being sampled at either 1- or 2-hour intervals in scintillation vials. At the end point, the skin surface was rinsed with three~l- ml aliquots of water, the skin discs were removed from the apparatus, and blotted with 1/3 of tissue paper (Kim Wipe) . The upper surface was tape-stripped 9 times with Scotch transparent tape to obtain the stratum corneum, and the epidermis was separated from the dermis with a scalpel. Analysis by liquid scintillation spectrometry included all samples necessary to account for complete balance and recovery of the radiolabelled material, including product retained on the applicator during delivery, the water-rinsed and excess removed on the tissue, tape stripped stratum corneum, epidermis, dermis (counted after NCS digestion) , receptor fluid, the empty Bronaugh cells, filter papers, and rinse pipettes. Theoretical applied dose was determined by subtracting the material retained on the applicator from the mean measured radioactivity of a minimum of six weighed 2-μL aliquots of the radiolabelled test product. Data were reported as percent-of-dose in tissue fractions. A p -value of < 0.1 was considered statistically significant.
Polyethylene glycol effect on delivery was tested for Base Formula A with molecular weight of 200D and 8KD.
The results obtained are summarised in Tables 7A and 7B ,
Table 7A
Figure imgf000038_0001
Table 7B
Figure imgf000039_0001
It can be seen from the results in Tables 7A and 7B that the addition of 5% polyethylene glycol did not adversely affect the delivery of glycolic acid to different skin tissue layers. In fact, the presence of PEG led to a directional increase in the combined delivery of glycolic acid to skin tissues (corneum, epidermis and dermis)
Thus, the results of Examples 1 - 5 demonstrate that polyethylene glycol reduced the sting caused by weak acids. Other known anti-irritants, such as hydrocortisone, as well as a polysaccharide, arabinogalactan, did not reduce the sting caused by weak carboxylic acids (Comparative Example 6) . Unlike numerous prior art approaches, the addition of PEG did not adversely affect the delivery of actives to skin layers (Example 7) . EXAMPLE 8
Example 8 illustrates topical compositions according to the present invention. The compositions can be processed in a conventional manner and are suitable for cosmetic use. In particular, the compositions are suitable for application to aged and/or UV-damaged skin to improve the appearance and the feel thereof as well as for application to healthy skin to prevent or retard deterioration thereof.
A typical oil-in-water emulsion within the scope of the invention is as follows:
Chemical name wt . %
PEG 10KD 4 glycolic acid 7 propylene glycol 1 glycerin 1 hydroxyethylcellulose 0. ,5 magnesium aluminum si!licateO . ,5 imidazolidinyl urea 0. .5 tetrasodium EDTA 0. 05 petrolatum 2 isopropyl palmitate 5 dimethicone 0. .5 cholesterol 0. 5 cetyl alcohol 0. 5 isostearic acid 3 peg-40 stearate 1 peg-100 stearate 1 sorbitan stearate 1 ammonium hydroxide to pH 4. 0 water DI qs to 1003 ) Another typical oil-in-water emulsion within the scope of the invention is as follows:
Chemical name wt . %
Polyethylene Glycol 40KD 5 glycolic acid 1C ) propylene glycol 1 hydroxyethylcellulose 0. 5 magnesium aluminum silicate 0. 5 imidazolidinyl urea 0. 2 petrolatum 2 isopropyl palmitate 5 dimethicone 0. 5 cholesterol 0. 5 stearic acid 3 isostearic acid 1. 5 glycerol stearate 1. 5 peg-40 stearate 1 peg-100 stearate 1 sorbitan stearate 1 cetyl alcohol 0. .5 ammonium hydroxide to pH 3 , .8 water DI qs to 100%
A typical water- in-oil dispersion within the scope of the invention is as follows:
Chemical name wt . % isostearyl neopentanoate 20 peg- 8 caprylic/capric glycerides 6 cetyl octanoate 17 polyglyceryl-6 dioleate 15 cyclomethicone 20 glyceryl isostearate 0.5 isostearic acid 0.5 ceramide III 0.1 ppg-5-cetheth-20 3 L-lactic acid/potassium lactate 6 hydroxycaprylic acid 0.1 water DI (to 100) 1.3
Polyethylene Glycol 200D 10
The following oil-in-water emulsion within the scope of the invention is prepared:
Chemical name wt . % xanthan gum 0.2 disodium EDT 0.1 sodium PCA 0.5 diazodinyl urea 0.3 titanium dioxide 1 stearic acid 3 cyclomethicone 0.3 cetyl alcohol 0.5 glyceryl stearate 0.5 peg-100 stearate 0.5 steareth-2 0.2 lecithin 0.5 tocopherol 0.2 octyl methoxycinnamate 6 polyethylene glycol 20KD 6 glycolic acid 3 malic acid 2 lactic acid 2 triethanolamine to pH 3.8 water DI qs to 100%
It should be understood that the specific forms of the invention herein illustrated and described are intended to be representative only. Changes, including but not limited to those suggested in this specification, may be made in the illustrated embodiments without departing from the clear teachings of the disclosure. Accordingly, reference should be made to the following appended claims in determining the full scope of the invention.

Claims

CLAIMS :
l.A method of reducing skin irritation or sting from a weak carboxylic acid, the method comprising topically applying a composition comprising the weak carboxylic acid and polyethylene glycol in a cosmetically acceptable vehicle.
2. A method according to claim 1 wherein the weak carboxylic acid has pKa of above about 2.
3. A method according to claim 2, wherein the acid is glycolic acid, lactic acid, malic acid, beta hydroxybutyric acid, acetic acid, succinic acid, citric acid, ascorbic acid, salicylic acid or oxamic acid, or mixtures thereof.
4. A method according to any one of the preceding claims, wherein the pH of the composition is in the range of from 3 to 6.
5. A method according to any one of the preceding claims wherein the molecular weight of polyethylene glycol is from 200D to 20,000D.
6. A method according any one of the preceding claims wherein the amount of polyethylene glycol is from 0.1 to 20 wt.%.
7. A method according to any one of the preceding claims wherein the composition is an oil-in-water emulsion.
8. A method according to any one of the preceding claims wherein the method is carried out at pH 2.5 to 10.
9. A method according to claim 8 wherein the method is carried out at pH 3-6.
PCT/EP2000/007303 1999-08-20 2000-07-31 A method for reducing skin irritation and sting from weak carboxylic acid WO2001013877A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69881/00A AU6988100A (en) 1999-08-20 2000-07-31 A method for reducing skin irritation and sting from weak carboxylic acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15011299P 1999-08-20 1999-08-20
US60/150,112 1999-08-20

Publications (1)

Publication Number Publication Date
WO2001013877A1 true WO2001013877A1 (en) 2001-03-01

Family

ID=22533167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007303 WO2001013877A1 (en) 1999-08-20 2000-07-31 A method for reducing skin irritation and sting from weak carboxylic acid

Country Status (2)

Country Link
AU (1) AU6988100A (en)
WO (1) WO2001013877A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1173467A (en) * 1966-04-12 1969-12-10 United Aircraft Corp Gas Discharge Structures for Gas Turbine Engines
FR2841135A1 (en) * 2002-06-25 2003-12-26 Oreal Evaluation of cutaneous neurosensitivity comprises applying composition, that comprises of a peripheral nervous system stimulant, to the skin
EP1374913A1 (en) * 2002-06-25 2004-01-02 L'oreal Nontherapeutic process for evaluating cutaneous neurosensitivity, corresponding kit and its use
WO2008074634A1 (en) * 2006-12-18 2008-06-26 Aco Hud Nordic Ab Topical formulations having reduced stinging potential
EP1941859A1 (en) * 2006-12-18 2008-07-09 ACO Hud Nordic AB Topical formulations
US8100830B2 (en) 2002-06-25 2012-01-24 Societe L'oreal S.A. Non-therapeutic methods of evaluating skin neurosensitivity, kit and use of a kit for implementing the method
WO2015000478A1 (en) * 2013-07-02 2015-01-08 Henkel Ag & Co. Kgaa Cleansing composition with high fatty acid content
US9211275B2 (en) 2008-01-04 2015-12-15 Isis Innovation Ltd. Ketone bodies and ketone body esters as blood lipid lowering agents
US9579302B2 (en) 2012-11-05 2017-02-28 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
US10051880B2 (en) 2008-08-21 2018-08-21 Oxford University Innovation Limited Hydroxybutyrate ester and medical use thereof
US10660958B2 (en) 2010-02-22 2020-05-26 Tdeltas Limited Nutritional composition
US10821062B2 (en) 2013-03-12 2020-11-03 Tdeltas Limited Compound for use in protecting skin
US11230722B2 (en) 2003-06-03 2022-01-25 Oxford University Innovation Limited Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535025A (en) * 1978-09-05 1980-03-11 Akira Oota Liquid remedy for dermatophytosis and its preparation
US5320838A (en) * 1992-12-21 1994-06-14 Pro Cure Products, Ltd. Protectant for irritated skin containing polyethyleneglycols, polyvinylether salt anhydride and polyvinylpyrrolidone
EP0729745A1 (en) * 1995-02-28 1996-09-04 Unilever Plc Vitamin C delivery system
US5736567A (en) * 1995-07-25 1998-04-07 L'oreal Stable composition containing ascorbic acid
US5879688A (en) * 1995-03-09 1999-03-09 Focal, Inc. Hydroxy-acid cosmetics
US5885593A (en) * 1995-09-28 1999-03-23 The Andrew Jergens Company Skin care composition including cyclodextrin materials and method for treating skin therewith
US5925679A (en) * 1995-06-06 1999-07-20 Neutrogena Corporation Topical vehicles containing solubilized and stabilized azelaic acid
WO1999038488A2 (en) * 1998-01-29 1999-08-05 Unilever Plc Skin cleansing bar
US5935584A (en) * 1994-01-13 1999-08-10 Elizabeth Arden Company Vitamin C delivery system

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535025A (en) * 1978-09-05 1980-03-11 Akira Oota Liquid remedy for dermatophytosis and its preparation
US5320838A (en) * 1992-12-21 1994-06-14 Pro Cure Products, Ltd. Protectant for irritated skin containing polyethyleneglycols, polyvinylether salt anhydride and polyvinylpyrrolidone
US5935584A (en) * 1994-01-13 1999-08-10 Elizabeth Arden Company Vitamin C delivery system
EP0729745A1 (en) * 1995-02-28 1996-09-04 Unilever Plc Vitamin C delivery system
US5879688A (en) * 1995-03-09 1999-03-09 Focal, Inc. Hydroxy-acid cosmetics
US5925679A (en) * 1995-06-06 1999-07-20 Neutrogena Corporation Topical vehicles containing solubilized and stabilized azelaic acid
US5736567A (en) * 1995-07-25 1998-04-07 L'oreal Stable composition containing ascorbic acid
US5885593A (en) * 1995-09-28 1999-03-23 The Andrew Jergens Company Skin care composition including cyclodextrin materials and method for treating skin therewith
WO1999038488A2 (en) * 1998-01-29 1999-08-05 Unilever Plc Skin cleansing bar

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 004, no. 069 (C - 011) 22 May 1980 (1980-05-22) *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1173467A (en) * 1966-04-12 1969-12-10 United Aircraft Corp Gas Discharge Structures for Gas Turbine Engines
FR2841135A1 (en) * 2002-06-25 2003-12-26 Oreal Evaluation of cutaneous neurosensitivity comprises applying composition, that comprises of a peripheral nervous system stimulant, to the skin
EP1374913A1 (en) * 2002-06-25 2004-01-02 L'oreal Nontherapeutic process for evaluating cutaneous neurosensitivity, corresponding kit and its use
US8100830B2 (en) 2002-06-25 2012-01-24 Societe L'oreal S.A. Non-therapeutic methods of evaluating skin neurosensitivity, kit and use of a kit for implementing the method
US11230722B2 (en) 2003-06-03 2022-01-25 Oxford University Innovation Limited Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
WO2008074634A1 (en) * 2006-12-18 2008-06-26 Aco Hud Nordic Ab Topical formulations having reduced stinging potential
EP1941859A1 (en) * 2006-12-18 2008-07-09 ACO Hud Nordic AB Topical formulations
EP1941860A1 (en) * 2006-12-18 2008-07-09 ACO Hud Nordic AB Topical formulations
US10154982B2 (en) 2008-01-04 2018-12-18 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US11311509B2 (en) 2008-01-04 2022-04-26 Oxford University Innovation Limited Ketone bodies and ketone body esters as blood lipid lowering agents
US9211275B2 (en) 2008-01-04 2015-12-15 Isis Innovation Ltd. Ketone bodies and ketone body esters as blood lipid lowering agents
US10051880B2 (en) 2008-08-21 2018-08-21 Oxford University Innovation Limited Hydroxybutyrate ester and medical use thereof
US10660958B2 (en) 2010-02-22 2020-05-26 Tdeltas Limited Nutritional composition
US11571479B2 (en) 2010-02-22 2023-02-07 Tdeltas Nutritional composition
US10478415B2 (en) 2012-11-05 2019-11-19 Tdeltas Limited Ketone bodies to protect tissues from damage by ionizing radiation
US9579302B2 (en) 2012-11-05 2017-02-28 Tdeltas Ketone bodies to protect tissues from damage by ionizing radiation
US11234953B2 (en) 2012-11-05 2022-02-01 Tdeltas Limited Ketone bodies to protect tissues from damage by ionizing radiation
US10821062B2 (en) 2013-03-12 2020-11-03 Tdeltas Limited Compound for use in protecting skin
US10639246B2 (en) 2013-07-02 2020-05-05 Henkel Ag & Co. Kgaa Cleansing composition with high fatty acid content
US20160101027A1 (en) * 2013-07-02 2016-04-14 Henkel Ag & Co. Kgaa Cleansing composition with high fatty acid content
WO2015000478A1 (en) * 2013-07-02 2015-01-08 Henkel Ag & Co. Kgaa Cleansing composition with high fatty acid content

Also Published As

Publication number Publication date
AU6988100A (en) 2001-03-19

Similar Documents

Publication Publication Date Title
US6440432B1 (en) Skin cosmetic compositions containing dextran or maltodextrin and a weak carboxylic acid
TW568789B (en) Compositions containing hydroxy acids or retinoids
EP0456459B1 (en) Cosmetic composition
US5744148A (en) Stabilization of an unstable retinoid in oil-in-water emulsions for skin care compositions
KR100803817B1 (en) Echinacea extract as anti-irritant and anti-aging booster in cosmetic compositions
CN101048200B (en) Personal care compositions with silicones and dihydroxypropyl trialkyl ammonium salts
US5759557A (en) Skin care composition
KR20050012805A (en) Cosmetic compositions comprising silicates
KR19980019155A (en) Irritating seed oil of irritation in hydroxy acid or retinoid containing compositions
EP0435483A2 (en) Cosmetic composition
EP0586235B1 (en) Antiperspirant actives containing titanium salts and compositions
WO2001013877A1 (en) A method for reducing skin irritation and sting from weak carboxylic acid
US6610741B1 (en) Skin cosmetic compositions containing a weak carboxylic acid and random copolymers of ethylene oxides and propylene oxides
US20050281853A1 (en) Skin compatible cosmetic compositions and delivery methods therefor
JP2003055149A (en) Skin care preparation
US20020018792A1 (en) Skin care anti-sebum compositions containing 3,4,4-trichlorocarbanilide
AU713391B2 (en) Antiperspirant actives and compositions
US20040247631A1 (en) Increasing the skin-moisturizing properties of polyols
JPH1045526A (en) Emulsion system for whitening cosmetic composition
MXPA01009293A (en) Skin cosmetic composition
MXPA97006435A (en) Stabilization of a non-stable retinoid in emulsions of oil in water for compositions for the care of the p
JP2571493C (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP